MedTrace Logo

Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas

NCT02454634 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2018-11-07

No results posted yet for this study

Summary

The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrogenase type 1) peptide vaccine targeting the IDH1R132H mutation (amino acid exchange from arginine to glutamine at position 132 of IDH1). The aim of this trial is to evaluate the safety and tolerability of and immune response to the IDH1 peptide vaccine in patients with IDH1R132H-mutated, WHO grade III-IV gliomas.

Conditions

Interventions

DRUG

IDH1 peptide vaccine

Sponsors & Collaborators

  • University Hospital Heidelberg

    collaborator OTHER

  • German Cancer Research Center

    collaborator OTHER

  • Neuro-Oncology Working Group of the German Cancer Society

    collaborator NETWORK

  • National Center for Tumor Diseases, Heidelberg

    lead OTHER

Principal Investigators

  • Michael Platten, MD · University Hospital Heidelberg, Neurology Clinic; Neurooncology Program at the NCT

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-09-19
Completion
2017-09-19

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02454634 on ClinicalTrials.gov